Artiva Biotherapeutics, Inc. ARTV Accrued Research And Development Expenses Current
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept artv:AccruedResearchAndDevelopmentExpensesCurrent.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s accrued research and development expenses current.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s accrued research and development expenses current?
- Artiva Biotherapeutics, Inc. (ARTV) reported accrued research and development expenses current of $1.05M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s accrued research and development expenses current changed year-over-year?
- Artiva Biotherapeutics, Inc.'s accrued research and development expenses current increased by 4.8% year-over-year, from $1M to $1.05M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s accrued research and development expenses current?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s accrued research and development expenses current has grown at a -45.2% compound annual growth rate (CAGR), from $2.86M to $858K.